Peptron

087010.KQ

74.23 USD

4.42

+6.33%

Overview

Last close

74.23 usd

Market cap

1.14B usd

52 week high

262.86 usd

52 week low

61.83 usd

Target price

26.22 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

373.306

Price/Book Value

16.7672

Enterprise Value

1.59B usd

EV/Revenue

354.4353

EV/EBITDA

-17.5233

Key financials

Revenue TTM

4.35M usd

Gross Profit TTM

3.35M usd

EBITDA TTM

-8.04M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

108.54M usd

Net debt

11.61M usd

About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.